PCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pacira Biosciences Inc (PCRX) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive catalysts, the current financial performance, insider selling trends, and technical indicators suggest a cautious approach. Holding off for now may be prudent.
The MACD is slightly positive, indicating mild bullish momentum, but the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 22.343, with resistance at 23.531 and support at 21.155. The pre-market price of 22.02 is below the pivot, suggesting potential downward pressure.
Revenue for 2025 increased to $726 million, with a strong growth target of assisting 3 million patients by
Patent settlement extending EXPAREL's exclusivity through
Collaboration with LG Chem to enhance commercialization in Asia-Pacific markets, with revenue expected to begin in 2027.
Insiders are selling heavily, with a 928.27% increase in selling over the last month.
Net income and EPS have dropped significantly YoY (-89.79% and -88.57%, respectively).
Pre-market price is down 3.67%, and the broader market (S&P
is also down 1.23%.
In Q4 2025, revenue increased by 5.14% YoY to $196.87 million, and gross margin improved to 72.26%. However, net income dropped sharply by 89.79% YoY to $1.64 million, and EPS fell by 88.57% YoY to 0.04, indicating profitability challenges.
Barclays initiated coverage with an Equal Weight rating and a $27 price target. The firm sees opportunities in the specialty pharmaceuticals sector but notes that the industry is in a transition phase, with improving investor sentiment and easing pricing headwinds.
